The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Venetoclax combinations in mutant AML subtypes podcast: FLT3

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Naval Daver, MD Anderson Cancer Center, Houston, US, about venetoclax combinations in patients with FLT3-mutated AML.

Venetoclax combinations in mutant AML subtypes podcast: FLT3

Emerging data on venetoclax combinations in patients with FLT3-mutated AML have been presented at ASH 2020. FLT3 mutations are the most common mutations in patients with AML.

In this podcast, Daver discusses the results of a study comparing the combination of azacitidine plus venetoclax versus azacitidine plus placebo in patients with FLT3-mutated AML. He also talks about a study evaluating the combination of gilteritinib with venetoclax in patients with relapsed/refractory FLT3-mutated AML and reports the results of the first combination of decitabine + venetoclax + FLT3 inhibitor of clinician’s choice in patients with FLT3-mutated AML.

 

Share: